1. Home
  2. OSPN vs CGEM Comparison

OSPN vs CGEM Comparison

Compare OSPN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneSpan Inc.

OSPN

OneSpan Inc.

N/A

Current Price

$22.57

Market Cap

946.7M

Sector

Technology

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$9.08

Market Cap

999.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OSPN
CGEM
Founded
1991
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
946.7M
999.4M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
OSPN
CGEM
Price
$22.57
$9.08
Analyst Decision
Hold
Strong Buy
Analyst Count
4
12
Target Price
$23.50
★ $34.70
AVG Volume (30 Days)
★ 876.8K
792.7K
Earning Date
10-29-2026
11-10-2026
Dividend Yield
★ 2.27%
N/A
EPS Growth
★ 28.77
N/A
EPS
★ 0.68
N/A
Revenue
★ $243,180,000.00
N/A
Revenue This Year
$5.28
N/A
Revenue Next Year
$2.44
N/A
P/E Ratio
$33.63
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$10.07
$8.47
52 Week High
$27.45
$23.19

Technical Indicators

Market Signals
Indicator
OSPN
CGEM
Relative Strength Index (RSI) 56.88 26.57
Support Level $21.29 N/A
Resistance Level $27.45 $16.31
Average True Range (ATR) 1.12 1.22
MACD -0.16 -0.27
Stochastic Oscillator 27.78 5.18

Price Performance

Historical Comparison
OSPN
CGEM

About OSPN OneSpan Inc.

OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: